{"id":684911,"date":"2022-09-13T16:34:05","date_gmt":"2022-09-13T20:34:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/conformis-actera-hip-system-receives-510k-clearance-from-the-u-s-food-and-drug-administration\/"},"modified":"2022-09-13T16:34:05","modified_gmt":"2022-09-13T20:34:05","slug":"conformis-actera-hip-system-receives-510k-clearance-from-the-u-s-food-and-drug-administration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/conformis-actera-hip-system-receives-510k-clearance-from-the-u-s-food-and-drug-administration\/","title":{"rendered":"Conformis Actera\u2122 Hip System Receives 510(k) Clearance from the U.S. Food and Drug Administration"},"content":{"rendered":"

\nNew design adds increasingly more common tri-taper femoral stem design and direct anterior approaches to the expanding Conformis family of Personalized Total Hip Arthroplasty implants
\n<\/h2>\n
\n

BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Company\u2019s Actera\u2122 Hip System.<\/p>\n

Actera adds a tri-taper femoral stem design to the expanding Conformis hip portfolio. This advanced tri-taper design is becoming more common among orthopedic surgeons, as its design objective is to facilitate a minimally invasive approach similar to direct anterior, with easier access to the femur and consequently less injury to muscles and fewer potential interactions with nerves.<\/p>\n

\u201cWe\u2019re excited to expand Conformis\u2019 hip portfolio with the addition of Actera, to satisfy the rise in surgeon demand for tri-taper stems,\u201d said Mark Augusti, Chief Executive Officer and President of Conformis. \u201cSurgeons have demonstrated a significant and growing preference for anterior total hip arthroplasty (THA) surgeries in recent years, and the innovative tri-taper stem is designed for easier placement. Peer-reviewed studies provide an increasing body of evidence that a tri-taper stem supports improved proximal load transfer and lower likelihood of implant loosening.\u201d<\/p>\n

Conformis will introduce the Actera hip system under a limited market release in select U.S. markets, which is expected to commence in the coming months. This complete THA system and supporting software has been developed to offer more personalized alternatives to cementless hip stems on market, while leveraging the Company\u2019s advanced surgical planning and surgery in a box delivery model.<\/p>\n

\u201cThe Actera hip, with its tri-tapered stem, is the natural evolution of the Conformis personalized portfolio,\u201d said Dr. Robert T. Trousdale, M.D., a Board-certified orthopedic surgeon at the Mayo Clinic in Rochester, MN. \u201cIt is well-suited to whichever surgical approach is chosen by the surgeon.\u201d<\/p>\n

\n Chronology of the Conformis Hip Portfolio:<\/strong>\n <\/p>\n